1. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. (16th February 2017) Authors: Bendell, Johanna C.; Hochster, Howard; Hart, Lowell L.; Firdaus, Irfan; Mace, Joseph R.; McFarlane, Joshua J.; Kozloff, Mark; Catenacci, Daniel; Hsu, Jessie J.; Hack, Stephen P.; Shames, David S.; Phan, See‐Chun; Koeppen, Hartmut; Cohn, Allen L. Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. (March 2017) Authors: Bendell, Johanna C.; Hochster, Howard; Hart, Lowell L.; Firdaus, Irfan; Mace, Joseph R.; McFarlane, Joshua J.; Kozloff, Mark; Catenacci, Daniel; Hsu, Jessie J.; Hack, Stephen P.; Shames, David S.; Phan, See‐Chun; Koeppen, Hartmut; Cohn, Allen L. Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. (October 2018) Authors: Wong, Gabrielle; Zhou, Jin; Liu, Jie; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven; Puschhof, Jens; McFarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit Journal: Nature medicine Issue: Volume 24:Number 10(2018) Page Start: 1627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Biliary cancer: Utility of next‐generation sequencing for clinical management. Issue 24 (13th September 2016) Authors: Javle, Milind; Bekaii‐Saab, Tanios; Jain, Apurva; Wang, Ying; Kelley, Robin Katie; Wang, Kai; Kang, Hyunseon C.; Catenacci, Daniel; Ali, Siraj; Krishnan, Sunil; Ahn, Daniel; Bocobo, Andrea Grace; Zuo, Mingxin; Kaseb, Ahmed; Miller, Vincent; Stephens, Philip J.; Meric‐Bernstam, Funda; Shroff, Rach... Journal: Cancer Issue: Volume 122:Issue 24(2016) Page Start: 3838 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Morphologic and molecular analysis of early‐onset gastric cancer. Issue 1 (13th October 2020) Authors: Setia, Namrata; Wang, Cindy X.; Lager, Angela; Maron, Steve; Shroff, Stuti; Arndt, Nicole; Peterson, Bryan; Kupfer, Sonia S.; Ma, Changqing; Misdraji, Joseph; Catenacci, Daniel; Hart, John Journal: Cancer Issue: Volume 127:Issue 1(2021) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Issue 6 (June 2016) Authors: Muro, Kei; Chung, Hyun Cheol; Shankaran, Veena; Geva, Ravit; Catenacci, Daniel; Gupta, Shilpa; Eder, Joseph Paul; Golan, Talia; Le, Dung T; Burtness, Barbara; McRee, Autumn J; Lin, Chia-Chi; Pathiraja, Kumudu; Lunceford, Jared; Emancipator, Kenneth; Juco, Jonathan; Koshiji, Minori; Bang, Yung-Jue Journal: Lancet oncology Issue: Volume 17:Issue 6(2016:Jun.) Page Start: 717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Issue 3 (16th October 2017) Authors: de W. Marsh, Robert; Talamonti, Mark S.; Baker, Marshall S.; Posner, Mitchell; Roggin, Kevin; Matthews, Jeffrey; Catenacci, Daniel; Kozloff, Mark; Polite, Blase; Britto, Michele; Wang, Chi; Kindler, Hedy Journal: Journal of surgical oncology Issue: Volume 117:Issue 3(2018) Page Start: 354 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Issue 5 (May 2023) Authors: Strickler, John H; Cercek, Andrea; Siena, Salvatore; André, Thierry; Ng, Kimmie; Van Cutsem, Eric; Wu, Christina; Paulson, Andrew S; Hubbard, Joleen M; Coveler, Andrew L; Fountzilas, Christos; Kardosh, Adel; Kasi, Pashtoon M; Lenz, Heinz-Josef; Ciombor, Kristen K; Elez, Elena; Bajor, David L; Cre... Journal: Lancet oncology Issue: Volume 24:Issue 5(2023) Page Start: 496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗